Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qing-Luo-Yin is a traditional Chinese medicine (TCM) formula composed of four main herbs: Sophora flavescens (Kushen), Sinomenium acutum (Qingfengteng), Phellodendron chinense (Huangbai), and Dioscorea collettii var. hypoglauca (Bixie)[2][3]. Originally developed by Jiren Li, a contemporary TCM master, it is used to treat "Hot Syndrome" patterns, most notably rheumatoid arthritis (RA), as well as traditional summer-heat ("shu wen") syndromes such as hyperthermia and heatstroke[1][2][3][7]. The principal mechanism of action appears to be immunomodulation, including inhibition of angiogenesis, inflammation, nucleotide metabolism, and immune functions. Active constituents, such as matrine, berberine, and sinomenine, contribute to anti-rheumatic, anti-inflammatory, and immunosuppressive activities through effects on pathways including purine and pyrimidine metabolism, suppression of pro-inflammatory cytokines, modulation of monocyte/macrophage polarization, and PPAR-γ activation. The formula has also demonstrated a protective effect against methotrexate-induced hepatic injury in animal models and has historical use in TCM for clearing summer-heat and resolving dampness[1][2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qing-luo-yin.